Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 13Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 6Neoplasm Metastasis 5Neoplasms 4Lung Neoplasms 4Brain Neoplasms 4Triple Negative Breast Neoplasms 2Skin Neoplasms 2Skin Diseases 2Pancreatic Neoplasms 2Hematologic Neoplasms 2Uveal Melanoma 1Spinocerebellar Degenerations 1Solid Tumors Harboring a BRAF V600 Mutation 1Soft Tissue Neoplasms 1Peripheral Nervous System Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Noonan Syndrome 5 1Neurofibromatosis 1 1Neurofibromatoses 1Neurofibroma, Plexiform 1Neurofibroma 1Multiple Myeloma 1Lymphoma 1Lymphatic Metastasis 1Low-grade Serous Ovarian Cancer 1Leukemia, Myeloid, Acute 1Hereditary Sensory and Autonomic Neuropathies 1Gliosarcoma 1

Interventions

encorafenib 1binimetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Advanced BRAF Mutant Cancers × binimetinib × Clear all
NCT03843775 2024-10-21

A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
17 enrolled 9 charts

Advanced BRAF Mutant Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡